US patent for our Therapy

Therapy: Publication of the US patent grant. On February 14, 2017, the United States Patent and Trademark Office granted the patent for our therapy with No. 9,567,384 “Phosphorylation on the Thr-248 and/or Thr-250 residues of transcription factor E2F4 as a therapeutic target in pathological processes associated with somatic polyploidy”.